News | February 03, 2025
Nectar Lifesciences posts Q3 FY25 PAT at Rs. 7.84 Cr
Revenue from Operations for Q3 FY25 was Rs. 454.33 crore,
Revenue from Operations for Q3 FY25 was Rs. 454.33 crore,
AA Signature provides an innovative approach to treatment planning that focuses on patient outcomes
The Union Budget 2025-26 strengthens India's healthcare sector with an allocation of Rs. 99,858.56 crore, marking a 9.78% rise from Rs. 90,958.63 crore in 2024-25
Everolimus TFOS is a kinase inhibitor indicated in adult and paediatric patients aged one year and older with tuberous sclerosis complex for the treatment of subependymal giant cell astrocytoma
The group reported Q3FY25 operating revenue of Rs 3,821 crore, driven by sustained double-digit growth of 14 per cent in biosimilars
Mamilli last held the role of Chief Digital & Technology Officer and Group President for China, Brazil and Precision Animal Health at Zoetis
The company said it voluntarily paused production at the Gagillapur plant in September 2024 for risk assessment on account of the USFDA observations
BRAFTOVI combination regimen is the first and only targeted therapy approvedby the U.S. FDA for treatment-naïve patients with metastatic colorectal cancer with a BRAF V600E mutation
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
The company plans to fund this Capex through debt and internal accruals and expects the project to be completed by FY27
Subscribe To Our Newsletter & Stay Updated
